Your session is about to expire
← Back to Search
Chemotherapy for Triple Negative Breast Cancer
Study Summary
This trial is testing a new combination of drugs to treat Triple Negative Breast Cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have mild or no nerve damage.I haven't had major surgery in the last 2 weeks or still have major side effects from it.My breast cancer is triple-negative.I don't have any other cancers that could affect this treatment's safety or results.I do not have any severe health issues that could make this trial unsafe for me.I haven't had a heart attack or heart inflammation in the last 6 months.I am willing to use two effective birth control methods.I have not had a stroke or mini-stroke in the last 6 months.I have a known history of AIDS.I can care for myself and am up and about more than 50% of my waking hours.My breast cancer was confirmed with a needle or incisional biopsy.I am planning to have surgery to remove my breast tumor and check the nearby lymph nodes after chemotherapy.My recent tests show my organs are functioning well.Your doctor thinks you will live for at least 6 more months.I have been treated with carboplatin, paclitaxel, doxorubicin, or cyclophosphamide in the last 3 years.I have had a seizure in the last 6 months.I am currently on hormone replacement therapy or taking drugs like tamoxifen.I haven't taken any experimental drugs recently.I am currently on medication for an infection.I have had treatment aimed at curing my current breast cancer.I am a woman aged 18 or older.My breast cancer is at an early stage but may have spread to nearby lymph nodes.I have heart failure or my heart's pumping ability is below 50%.I don't have serious heart rhythm problems or I have a pacemaker.I understand and can follow the study's procedures.I have had myelodysplastic syndrome or acute myeloid leukemia.I have not had any major abdominal issues like a fistula, perforation, or abscess in the last 28 days.
- Group 1: Single arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies left for participation in this clinical investigation?
"The records available on clinicaltrials.gov indicate that this medical trial is not presently enrolling patients; it was initially posted in August 2019 and last updated January 28th 2022. Despite the cessation of recruitment for this specific study, there are still over 4,300 other trials accepting new participants at present."
What is the cap on participants for this research endeavor?
"At present, the trial has ceased recruiting new candidates. Initially posted on August 9th 2019 and last updated on January 28th 2022, this investigation is no longer accepting participants. However, there are 2351 studies for breast cancer currently open to enrollees and 1975 trials involving this treatment still admitting patients."
What is the typical application of this therapeutic procedure?
"This therapeutic intervention is typically used to facilitate remission in patients with lymphoma, non-Hodgkin's. It additionally has been proven effective at treating a variety of other conditions such as leukemia, Kaposi's Sarcoma related to AIDS and locally advanced Non-Small cell lung cancer (NSCLC)."
Does this trial represent a pioneering venture in its field?
"Since 1997, this therapeutic intervention has been subject to medical experimentation. Initially sponsored by Alfacell, the first trial enrolled 300 patients and eventually led to Phase 3 drug approval. At present, there are 1975 active trials for this treatment across 85 countries in 3800 cities."
Has the FDA certified this particular therapy?
"With Phase 2 data backing its safety but no evidence of efficacy, we give this medication a score of 2."
Share this study with friends
Copy Link
Messenger